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CD94 and a Novel Associated Protein (94AP)
Form a NK Cell Receptor Involved in the
Recognition of HLA-A, HLA-B, and HLA-C Allotypes
Joseph H. Phillips,* Chiwen Chang,* The striking structural differences between the
KIRs (immunoglobulin superfamily) and Ly49 receptorsJeanine Mattson,* Jenny E. Gumperz,†
Peter Parham,† and Lewis L. Lanier* (C-type lectin superfamily) have presented an intriguing
enigma. As yet, human homologs of the Ly49 genes and*Departments of Human Immunology
and Molecular Biology murine counterparts of the KIR have not been identified,
raising thepossibility that the inhibitory class I receptorsDNAX Research Institute of Molecular
and Cellular Biology arose independently in the two species as a conse-
quence of MHC divergence (Gumperz and Parham,901 California Avenue
Palo Alto, California 94304 1995). The Ly49 genes are on mouse chromosome 6,
linked to the NKR-P1 genes encoding C-type lectins†Departments of Microbiology and Immunology
and Structural Biology preferentially expressed on NK cells (Giorda et al., 1992;
Ryan et al., 1992; Yokoyama et al., 1990). Members ofStanford University
Stanford, California 94305 the C-type lectin superfamily encoding type II proteins
expressed on NK cells have been identified on human
chromosome 12 (syntenic with mouse chromosome 6),
including CD94 and a human NKR-P1 gene (Chang etSummary
al., 1995; Lanier et al., 1994).
CD94 is expressed on most NK cells and a subset ofWhereas the human killer cell inhibitory receptors
T lymphocytes (Aramburu et al., 1990, 1991). Studies to(KIRs) for HLA class I are immunoglobulin-like mono-
examine the function of CD94 have demonstrated thatmeric type I glycoproteins, the murine Ly49 receptors
anti-CD94 monoclonal antibodies (MAbs) can eitherfor H-2 are type II homodimers of the C-type lectin
augment, inhibit, or have no effect on NK cell–mediatedsuperfamily. Here, we demonstrate that human NK
cytotoxicity and cytokine production (Pe´rez-Villar et al.,cells also express C-type lectin receptors that influ-
1995). Such differences in behavior are seen comparingence recognition of polymorphic HLA-A, HLA-B, and
NK cell clones established from a single donor (Pe´rez-HLA-C molecules. These receptors are heterodimers
Villar et al., 1995). Moretta et al. (1994) have suggestedcomposed of CD94 chains covalently associated with
that CD94 is a specific receptor for HLA-B alleles of thenovel tyrosine-phosphorylated glycoproteins (94AP).
Bw6 serotype, based on the observation that certain NKSome NK clones recognize a common HLA-C ligand
cell clones expressing high levels of cell surface CD94using both KIRs and CD94–94AP receptors. These
are able to kill Epstein–Barr virus (EBV)-transformed Bfindings suggest the existence of human inhibitory
lymphoblastoid cell lines expressing HLA-B7 in the pres-MHC class I receptors of the immunoglobulin and
ence, butnot the absence of anti-CD94 MAb. In contrast,C-type lectin superfamilies and indicate overlap in li-
in an extensive analysis we have observed manygand specificity.
CD94bright1 NK cell clones that fail to recognize HLA-
B7 and for which the effect of anti-CD94 MAb on HLAIntroduction
recognition is more complicated. Moreover, the finding
that CD94 may be a single gene encoding a glycoproteinNatural killer (NK) cells preferentially kill targets lacking
essentially lacking a cytoplasmic domain, suggestedmajor histocompatibility complex (MHC) class I (Ljung-
that CD94 alone may not be capable of signal transduc-gren and Karre, 1985) and express receptors for class
tion. This inference led us to propose an alternativeI that are responsible for inhibition of cytotoxicity (re-
model in which CD94 associates with other proteinsviewed by Lanier and Phillips, 1996). While the nature of
involved in HLA recognition (Chang et al., 1995). Here,the interactions triggering NK cell–mediated cytotoxicity
we present evidence in support of this hypothesis.are not well defined, receptors for MHC class I have
been identified. In the mouse, the Ly49 genes, members
of the C-type lectin superfamily, encode type II mem- Results
brane glycoproteins that bind H-2 ligands (Brennan et
al., 1994; Daniels et al., 1994; Kane, 1994; Karlhofer et Effect of Anti-CD94 MAb on NK Cell Recognition
of HLA Class I Moleculesal., 1992; Mason et al., 1995; Stoneman et al., 1995).
The human killer cell inhibitory receptors (KIRs) respon- NK cell clones kill the class I–deficient 721.221 EBV-
transformed B lymphoblastoid cell line, but are hetero-sible for HLA class I recognition are type I membrane
glycoproteins with homology to the immunoglobulin su- geneous in their ability to lyse transfectants expressing
different HLA class I molecules (Litwin et al., 1993). Whileperfamily (Colonna and Samaridis, 1995; D’Andrea et
al., 1995; Wagtmann et al., 1995a). Both KIRs and Ly49 a prior study reported that NK cell clones expressing
high levels of CD94 are unable to kill target cells bearingreceptors are expressed on subsets of NK cells and
serve to inhibit cell-mediated cytotoxicity against cells HLA-B7 (Moretta et al., 1994), we were unable to observe
a directcorrelation between cell surface densityof CD94bearing appropriate MHC class I allotypes. Recent stud-
ies have implicated the PTP1C tyrosine phosphatase in and HLA-B7 recognition in the analysis of 194 NK cell
clones derived from five different blood donors (Changthe inhibitory function of the KIR (Burshtyn et al., 1996;
Fry et al., 1996). et al., 1995). However, we have noted that anti-CD94
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721.221 target cells, but demonstrated diminished cyto-
toxicity against transfectants expressing HLA class I
molecules. Expression of class I on the transfectants
was clearly responsible for protection from NK cell lysis,
as addition of anti-HLA class I MAbrestored cytotoxicity
to levels comparable to killing of the class I–negative
721.221 cells (Figure 1). In the presence of F(ab9)2 frag-
ments of anti-CD94 MAb, NK cell lysis of transfectants
expressing certain HLA-A, HLA-B, and HLA-C molecules
was comparable to killing of the class I–negative 721.221
target. For NK cell clone NKA, the inhibition by HLA-
A*0211, HLA-A*2403, HLA-A*3601, HLA-B*0702, HLA-
Cw*0102, or HLA-Cw*0401 was reversed by anti-CD94
MAb (Figure 1A). For NK cell clone NKB, anti-CD94 MAb
affected recognition of HLA-A*0211, HLA-A*2403, HLA-
A*3601, HLA-B*0702, HLA-Cw*0102, HLA-Cw*0304,
HLA-Cw*0401, or HLA-Cw*0801. These effects were
sensitive to HLA class I polymorphism, because anti-
CD94 did not affect target cell protection conferred by
HLA-B*2705, HLA-B*5101, or HLA-B*5801 and, in the
case of NK clone NKA, did not affect recognition of HLA-
Cw*0401 (Figure 1).
Prior studies have shown that NK cell recognition of
HLA-Bw4, HLA-A3, and HLA-C are mediated by a family
of highly related receptors (Colonna et al., 1993; Dohring
et al., 1996; Gumperz et al., 1995; Wagtmann et al.,
1995a, 1995b). KIRs recognizing HLA-Bw4 ligands can
be detected using the DX9 MAb (Gumperz et al., 1995).
HLA-C alleles segregate into mutually exclusive groups
according to their recognition by KIRs and expression
of either S and N or N and K at amino acids 77 and 80
Figure 1. Effect of Anti-CD94 MAb on HLA Class I Recognition in the a1 domain of the class I heavy chain (Colonna et
NK cell clones NKA and NKB were assayed for lysis of 721.221 al., 1993). KIRs recognizing HLA-C alleles with S77 and
target cells or 721.221 transfectants expressing the indicated
N80 are recognized by the GL183 MAb (Moretta et al.,HLA-A, HLA-B, or HLA-C alleles in the presence or absence of
1993), whereas KIRs recognizing HLA-C with N77 andcontrol IgG1, anti-CD94 (F(ab9)2 fragments of HP-3D9), or anti-HLA
K80 are detected with either the EB6 (Moretta et al.,class I (DX15 and DX17) MAbs. MAbs were used at 2.5 mg/ml. The
effector to target cell ratio was 3:1. Clones NKA and NKB were 1993) or HP-3E4 MAb (Lanier et al., 1995). Analysis of
established from an individual with the HLA haplotype A1, A68, B14 the HLA specificity of NK cell clones is complicated by
(Bw6), B57 (Bw4), Cw6. The KIR phenotype of clone NKA is NKB11, the fact that several KIRs can be expressed simultane-
GL1832, HP-3E41, and clone NKB is NKB11, GL1832, HP-3E42. MAb
ously on the cell surface of an individual NK cell cloneDX9 against NKB1 reversed the protection conferred by the HLA-
(Lanier et al., 1995; Litwin et al., 1993; Moretta et al.,B alleles of the Bw4 serotype (i.e., HLA-B*2705, HLA-B*5101, and
1990). Moreover, KIRs recognizing HLA-B and HLA-CHLA-B*5801) (data not shown). Clone NKA also expresses an HP-
3E41 KIR recognizing HLA-C*0401, potentially explaining the inabil- ligands function independently in NK cell clones (Lanier
ity of anti-CD94 MAb to affect lysis of this transfectant (see Figure et al., 1995). Our observation that anti-CD94 MAb af-
2). In addition to the alleles shown in the figure, neither the NKA nor fected NK cell recognition of several HLA-C alleles
the NKB NK cell clone recognized HLA-B*1501 (Bw6), HLA-B*4601
raised the possibility that certain NK cell clones might(Bw6), HLA-B*5401 (Bw6), or HLA-B*5501 (Bw6) (i.e., these transfec-
express both a KIR and CD94-associated class I recep-tants were killed to the same extent as the untransfected 721.221
tor reactive with a common HLA-C allele. Therefore,cell line, data not shown).
we selected several KIR HP-3E41 NK cell clones and
assayed them for lysis of 721.221 cells expressing HLA-MAb affects HLA recognition by several NK cell clones
Cw*0401 in the presence or absence of either anti-CD94,and this prompted us to investigate this activity further.
HP-3E4, or both MAbs. Consistent with prior observa-In these experiments, CD941 NK cell clones were as-
tions (Lanier et al., 1995), many KIR HP-3E41 NK cellsayed for lysis of the 721.221 cell line or transfectants
clones were unable to kill 721.221 cells expressing HLA-expressing HLA-A, HLA-B, or HLA-C molecules in the
Cw*0401 or HLA-Cw*1503, unless assayed in the pres-presence or absence of anti-CD94 MAb. With many NK
ence of HP-3E4 MAb, which permits target cell lysis.clones, anti-CD94 MAb had no effect on the recognition
Although these NK cell clones express CD94, anti-CD94of any HLA-A,HLA-B, or HLA-Callele analyzed, although
MAb had no effect on the lysis of targets cells protectedall NK clones expressed CD94 on the cell surface. How-
by HLA-Cw*0401 or HLA-Cw*1503. A representative NKever, certain NK cell clones were able to kill the class I
cell clone of this phenotype is shown in Figure 2A. How-transfectants in the presence, but not in the absence,
ever, for certain KIR HP-3E41 NK cell clones the HP-of anti-CD94 MAb. Representative data from two NK
3E4 MAb was unable to augment lysis of transfectantscell clones that were affected by anti-CD94 MAb are
shown in Figure 1. NK clones NKA and NKB killed expressing HLA-Cw*0401, suggesting that such NK
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not in the absence, of anti-CD94 MAb. These findings
demonstrate that NK cell clones lacking the known KIRs
reactive with HLA-C can indeed recognize HLA-C mole-
cules and implicate CD94 in the process. In addition,
these EB62, GL1832 NK cell clones were able to recog-
nize certain HLA-A and HLA-B alleles (e.g., HLA-A*0201,
HLA-A*0211, HLA-A*2403, HLA-A*3601, HLA-B*0702)
and lysis of transfectants expressing those allotypes
was augmented in the presence of anti-CD94 MAb or
anti-class I MAb (Figure 3).
Evidence for a Tyrosine-Phosphorylated
CD94-Associated Glycoprotein
Recently, we cloned a cDNA encoding a type II protein
reactive with anti-CD94 MAb (Chang et al., 1995). Given
the functional effects of anti-CD94 MAb on NK cells, a
notable feature of the CD94 protein was its lack of any
significant cytoplasmic domain with which to transduce
signals. Because a search for additional CD94 cDNA
isoforms encoding a longer cytoplasmic region was un-
successful, an analysis at the protein level was therefore
undertaken. The predicted molecular mass of the poly-
peptide encoded by the CD94 cDNA is z20 kDa and
included in the amino acid sequence are two potential
sites for N-linked glycosylation (Chang et al., 1995). As
none of the existing anti-CD94 MAbs are functional in
Western blot analysis, we generated a polyclonal rabbit
antiserum against the entire extracellular domain of the
CD94 protein encoded by the cloned cDNA (Chang et
al., 1995). Specific antibodies were purified using a re-Figure 2. Effect of Anti-CD94 and Anti-KIR on HLA-C Recognition
combinant CD94 fusion protein Sepharose affinity col-CD941, KIR HP-3E41 NK cell clones NKC and NKD were assayed
for lysis of 721.221 target cells or 721.221 transfectants expressing umn. The polyclonal anti-CD94 antiserum reacted with
HLA-C*0401 or HLA-C*1503 in the presence or absence of control murine P815 cells transfected with CD94 cDNA, but not
IgG1, anti-CD94 (DX22), anti-KIR (HP-3E4 MAb), both anti-CD94 untransfected P815 cells or control transfectants, as
plus anti-KIR, or anti-HLA class I (DX15 and DX17) MAbs. MAbs determined by immunofluorescence and Western blot
were used at 2.5 mg/ml. The effector to target cell ratio was 3:1.
analysis (data not shown). Lysates were prepared fromThe HLA haplotype of the blood donor of NK clones NKC and NKD
NK cell clones and assayed by Western blotting usingwas not determined. The KIR phenotypes of NK cell clones NKC
and NKD are NKB12, GL1832, HP-3E41. the anti-CD94 serum. Analysis of 5 NK cell clones and
the Jurkat T leukemia cell line (used as a negative con-
trol) is shown in Figure 4, findings that represent the
results obtained using 25 different NK cell clones estab-clones possess a second inhibitory receptor for HLA-
Cw*0401. These particular NK cell clones were assayed lished from six individuals. Specific bands of z25–30
kDa were observed in the NK cell clones, consistentfor lysis of 221.Cw*0401 target cells in the presence of
anti-CD94, HP-3E4, or both MAbs. The NK clone NKD with the sizeof theCD94 glycoprotein predictedfrom the
cDNA sequence and observed on CD94 transfectants.failed to kill the 221.Cw*0401 transfectant in the pres-
ence of either anti-CD94 or HP-3E4 MAb; however, lysis However, Aramburu et al. (1990) previously demon-
strated that z43kDa glycoproteins were immunoprecip-was substantially augmented when both HP-3E4 and
anti-CD94 were present (Figure 2B).However, anti-CD94 itated from 125I-labeled NK cells. Because no proteins of
z43 kDa were detected in the Western blots using theMAb had no effect on target cell protection conferred
by HLA-Cw*1503 (also N77 and K80), whereas HP-3E4 polyclonal anti-CD94 serum, this discrepancy prompted
us to examine the structural basis for the difference.MAb alone permitted lysis of this target (Figure 2B). This
differential affect of anti-CD94 MAb on recognition of NK cell clones were labeled with 125I and lysates were
immunoprecipitated with anti-CD94 MAb. ConsistentHLA-Cw*0401 and HLA-Cw*1503 has been observed
using several NKcell clones from different blood donors. with the prior studies (Aramburu et al., 1990), a predomi-
nant z43 kDa 125I-labeled protein was immunoprecipi-To determine whether the effect of anti-CD94 MAb on
NKcell recognition of HLA-C molecules requires expres- tated by the anti-CD94 MAb (Figure 5A). After treatment
with N-glycosidase F to remove N-linked carbohydrates,sion of a KIR, we selected NK cell clones that did not
react with MAb HP-3E4, GL183, or EB6. As shown in this 125I-labeled protein was reduced in size to z26 kDa
(Figure 5A). The relative migration of this protein wasFigures 3A–3C, NK cell clones NKE, NKF, and NKG (all
HP-3E4, EB6, and GL183 negative) were able to kill unaffected by treatment with O-glycanase, suggesting
an absence of O-linked oligosaccharides (data not721.221 cells expressing HLA-Cw*0102, HLA-Cw*0304,
HLA-Cw*0401 and HLA-Cw*0801 in the presence, but shown). In contrast, when P815, Jurkat, or COS7 cells
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Figure 3. Effect of Anti-CD94 on HLA-C Recognition by KIR GL183- and EB6-Negative NK Cell Clones
NK cell clones NKE, NKF, and NKG (selected on the basis of not reacting with anti-KIR MAb HP-3E4, GL183, or DX9) were assayed for lysis
of 721.221 target cells or 721.221 transfectants expressing the indicated HLA-A, HLA-B, or HLA-C alleles in the presence or absence of control
IgG1, anti-CD94 (DX22), or anti-HLA class I (DX15 and DX17) MAbs. MAbs were used at 2.5 mg/ml. The effector to target cell ratio was 3:1.
Clones NKE, NKF, and NKG were established from an individual with the HLA haplotype A1, A29, B8, B13, Cw6, Cw7. In addition to the alleles
shown in the figure, NK cell clones NKE, NKF, and NKG did not recognize HLA-B*4601 (Bw6), HLA-B*5101 (Bw4), HLA-B*5401 (Bw6), HLA-
B*5501 (Bw6), or HLA-B*5801 (Bw4) (i.e., these transfectants were killed to the same extent as the untransfected 721.221 cell line, data not
shown).
transfected with CD94 cDNA were 125I labeled and CD94
protein immunoprecipitated with anti-CD94 MAb, 125I-
labeled CD94 antigens were not visualized (Figure 5A),
unless the autoradiographs were exposed for very pro-
longed time periods (revealing a faint z30 kDa band,
data not shown). This finding was observed in over 10
independent experiments. Because the CD941 P815
transfectants expressed CD94 cell surface antigen in
amounts equal to or greater than the NK cell clones,
this result suggested the protein encoded by the CD94
cDNA inefficiently labels with 125I.
The 125I-labeled protein immunoprecipitated from NK
cells by anti-CD94 MAb is a disulfide-bonded dimer,
migrating at z70 kDaunder nonreducing conditions and
z43 kDa under reducing conditions (Aramburu et al.,
1990). Because the protein encoded by the CD94 cDNA
poorly labels with 125I and the apparent molecular mass
of the 125I-labeled protein on NK cells is greater than that
obtained from CD94 transfectants or predicted from the
Figure 4. Western Blot Analysis of CD94 on NK Cell Clones cDNA sequence, we reasoned that the NK cells might
Lysates prepared from five NK cell clones (NKC43, NKD1, NKD19, express a heterodimer composed of a CD94 subunit
NKD61, and NKD67) and the Jurkat T leukemia cell line (negative disulfide-bonded to a second glycoprotein of z43 kDa
control) were separated by SDS–PAGE using 12% acrylamide gels (z26 kDa after removal of N-glycans) that is readily visu-
(5 3 105 cell equivalents of lysate per lane) and transferred to PVDF alized in 125I-labeled lysates. To test this model, NK cell
membranes. CD94 proteins were detected by Western blot analysis
clones and CD94-transfected P815 cells were labeledusing a polyclonal anti-CD94 antiserum and visualized by chemilu-
with 125I and used for immunoprecipitation with anti-minescence. Western blots incubated with normal rabbit serum or
CD94 MAb. After enzymatic removal of N-glycans, pro-HRP-conjugated anti-rabbit immunoglobulin were negative (data
not shown). teins were examined by SDS–PAGE and by Western blot
C-Type Lectin HLA Receptors
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Figure 5. Detection of 125I-Labeled CD94-Associated Proteins
Murine P815 cells stably transfected with human CD94 cDNA (Chang et al., 1995) and NK cell clones were labeled with 125I, lysed, and
immunoprecipitation was performed using control immunoglobulin (cIg) or anti-CD94 MAb HP-3D9 bound to protein G–Sepharose. Immunopre-
cipitates were treated with N-glycosidase F (N-gly), as indicated, to remove N-linked oligosaccharides, and then analyzed by SDS–PAGE
under reducing conditions using 12% acrylamide gels. Proteins were transferred to PVDF membranes and CD94 proteins were detected by
Western blot analysis using an affinity-purified polyclonal anti-CD94 antiserum. 125I-labeled proteins were detected by using a PhosphorImager.
Proteins detected by Western blot analysis were visualized by chemiluminescence.
(A) Detection of 125I-labeled proteins immunoprecipitated with anti-CD94 MAb from CD941 P815 transfectants and NK cell clone NKA6.
(B) Proteins immunoprecipitated with anti-CD94 MAb from CD941 P815 transfectants and NK cell clone NKA6 were analyzed by Western blot
analysis using affinity-purified polyclonal anti-CD94 antiserum.
(C) Detection of 125I-labeled proteins immunoprecipitated with anti-CD94 MAb from CD941 P815 transfectants and NK cell clones NK1, NK2,
NK19, and NK20. All immunoprecipitates were treated with N-glycosidase F before SDS–PAGE.
(D) Proteins immunoprecipitated with anti-CD94 MAb from CD941 P815 transfectants and NK cell clones NK1, NK2, NK19, and NK20 were
treated with N-glycosidase F and then were analyzed by Western blot analysis using affinity-purified polyclonal anti-CD94 antiserum. In (C)
and (D), control immunoprecipitates for CD941 P815 and NK20 are not shown on the figure, but were negative. Note that the CD94 bands of
z20 kDa and z21 kDa observed in the Western blots were present both in the CD941 P815 transfectant and the NK cell clones.
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analysis using the polyclonal anti-CD94 antiserum. As
shown in Figure 5A, no 125I proteins were visualized from
CD94 immunoprecipitates prepared from the CD941
P815 transfectants. However, Western blot analysis us-
ing the polyclonal anti-CD94 antiserum (Figure 5B) re-
vealed a predominant z20–21 kDa band after treatment
with N-glycosidase F, demonstrating that the anti-CD94
MAb immunoprecipitated a protein of the expected size.
By contrast, anti-CD94 MAb immunoprecipitated an 125I-
labeled protein of z43 kDa (z26 kDa after treatment
with N-glycosidase F) from the NK cell clone (Figure 5A).
Western blot analysis revealed that this 125I-labeled 26
kDa protein did not react with the polyclonal anti-CD94
antiserum, but that the NK cell clones express a z20–21
kDa CD94 protein of identical size to that observed in
the CD941 P815 transfectant (Figure 5B). Analysis of
four additional NK cell clones gave similar results (Fig-
ures 5C, 5D). In all NK clones examined, a z26 kDa 125I-
labeled protein was immunoprecipitated by anti-CD94
MAb; but only a z20–21 kDa CD94 protein was detected
in the immunoprecipitates by Western blot analysis.
These results demonstrate that NK cells possess a z20
kDa CD94 protein corresponding to the predicted size
of the CD94 cDNA-translated product and that the z26
kDa protein visualized by 125I in NK cell clones is not Figure 6. Tyrosine Phosphorylation of CD94-Associated Proteins
reactive with a polyclonal antiserum generated against A CD941 NK cell line was stimulated with pervanadate, lysed, and
the extracellular domain of the cloned CD94 gene immunoprecipitation was performed using control immunoglobulin
(cIg) or anti-CD94 MAb (DX22). Immunoprecipitates were resolvedproduct.
by SDS–PAGE under reducing conditions using 4%–20% acrylamideAnti-CD94 MAb effects NK cell function despite the
gels. Proteins were transferred to PVDF membranes and tyrosine-lack of a cytoplasmic domain in the CD94 molecule.
phosphorylated proteins were detected by Western blot analysis
Therefore, it seems likely that signal transduction may using HRP-conjugated anti-phosphotyrosine MAb (4G10). Proteins
involve the 26 kDa protein associated with CD94 rather detected by Western blot analysis were visualized by chemilumines-
than the 20 kDa CD94 subunit. To examine this possibil- cence.
ity, a CD941 NK cell line was stimulated with pervana-
date (an inhibitor of protein-tyrosine phosphatases that
this receptor in NK cell function. Using NK cell clonesinduces protein-tyrosine phosphorylation; O’Shea et al.,
established from a single individual, Pe´rez-Villar et al.1992), lysed, and immunoprecipitated with an anti-CD94
(1995) have shown that anti-CD94 MAb can either aug-MAb. Immunoprecipitates were analyzed by Western
ment, inhibit, or have no effect on the lysis of Fc recep-blot using an anti-phosphotyrosine MAb. As shown in
tor–bearing xenogeneic target cells. Additionally, Mor-Figure 6, a phosphotyrosine-containing glycoprotein of
etta et al. (1994) have reported that certain NK cellclonesz43 kD was detected in the anti-CD94 immunoprecipi-
kill HLA-B71 target cells in the presence, but not in thetate from the NK cell line.
absence, of anti-CD94 MAb. These investigators con-
cluded that CD94 is a specific receptor for HLA-B7 and
other class I molecules expressing the Bw6 serotype.Discussion
However, since essentially all NK cells express CD94
(Lopez-Botet, 1995) and in general only a minor subsetThe Ly49 receptors are type II membrane glycoproteins
encoded by z8 genes of the C-type lectin superfamily of NK cell clones in many individuals recognize HLA-B7
(Litwin et al., 1993), the CD94 molecule expressed on(reviewed by Yokoyama, 1995). Different Ly49 isoforms
bind distinct polymorphic H-2 class I molecules (Bren- most NK cells is probably not a specific receptor for
HLA-B7. Nonetheless, our studies have confirmed thatnan et al., 1994; Daniels et al., 1994; Kane, 1994), and
their diverse cytoplasmic domains suggest that these anti-CD94 MAb can affect recognition of HLA-B7 by
some NK cell clones, but the apparent involvement ofreceptors may transmit positive as well as negative sig-
nals (Smith et al.,1994; Wong et al., 1991). Humanhomo- CD94 in HLA recognition is more complex than appreci-
ated, likely due to the limited selection of NK cell cloneslogs of the Ly49 genes have not as yet been found.
Although also a member of theC-type lectin superfamily, and target cells previously analyzed.
We present evidence that anti-CD94 MAb can effectCD94 has only limited homology with murine Ly49 and
unlike Ly49 demonstrates a simple pattern on genomic NK cell killing of the 721.221 B lymphoblastoid cell line
transfected with certain HLA-A, HLA-B, or HLA-C genes.Southern blot analysis, suggesting that CD94 may be
encoded by a single gene (Chang et al., 1995). Comparison of the class I alleles recognized by different
NK cell clones and affected by anti-CD94 MAb failed toWhile the known structural features of CD94 make it
an unlikely candidate for a human Ly49 counterpart, provide a simple explanation for the specificity of this
putative class I receptor. In particular, in several NKthere are intriguing effects of anti-CD94 MAb implicating
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cell clones anti-CD94 MAb affected recognition of HLA- splicing; however, if this is the case it is surprising that
a polyclonal antiserum against the entire CD94 extracel-B*0702, but not other HLA-B alleles possessing the Bw6
serological epitope (e.g., HLA-B*1501), indicating that lular domain failed to react with this protein. Alterna-
tively, 94AP may be encoded by a different gene orCD94 receptors are not specific for Bw6. Neither was
there evidence that CD94 receptors recognize the Bw4 genes and these proteins may form heterodimers with
CD94 subunits. Because it disulfide-bonds to CD94, itmotif, because anti-CD94 MAb didnot affect recognition
of HLA-Bw4 alleles (e.g., HLA-B*5101, HLA-B*5801). seems likely that the 94AP is also a type II glycoprotein,
structurally similar to CD94. Several genes of the C-typeAmongst the HLA-C alleles, CD94 receptors failed to
discriminate the polymorphism at amino acids 77 and lectin superfamily encoding type II receptors preferen-
tially expressed on NK and T cells are present in the NK80 previously defined for the KIR molecules identified
by the EB6 and GL183 MAbs (Colonna et al., 1993). complex on human chromosome 12, making it possible
that the gene or genes encoding the 94AP will be foundHowever, it should be appreciated that analysis of the
HLA specificity of NK cells is complicated by the fact in this region.
125I-labeled CD94-associated glycoproteins have beenthat a single NK clone can simultaneously express two
or more KIRs that function independently (Lanier et al., detected on all NK cell clones examined, irrespective
of their class I specificity. While CD94–94AP receptors1995; Moretta et al., 1990; Wagtmann et al., 1995a).
Indeed, we have demonstrated that bothanti-CD94 MAb are clearly involved in recognition of certain class I mole-
cules, it is uncertain whether this complex is directlyand anti-KIR HP-3E4 MAb can affect recognition of HLA-
Cw*0401 by an individual NK cellclone, suggesting over- responsible for HLA recognition or serves as a corecep-
tor, similar to the role of the CD8ab heterodimer in Tlap in ligand specificity of these receptors. The effect of
anti-CD94 MAb on recognition of HLA-C was observed cell receptor recognition of class I. Comparison of differ-
ent NK cell clones has revealed subtle biochemical dif-even in NK cell clones that do not express KIRs reactive
with the EB6, HP-3E4, or GL183 MAbs, indicating that ferences in the 94AP molecules, suggesting that the
94AP may bestructurally heterogeneous (L. L. L., unpub-the EB6 and GL183 reactive KIRs are not required for
HLA-C recognition. Finally, with many NK cell clones lished data). If the 94AP are heterogeneous and differen-
tially expressed in NK cell clones, this could accountanti-CD94 MAb had no effect on recognition of any class
I molecule examined, although if these NK cell clones for the unexplained functional effects of anti-CD94 MAb
on different NK cells and on the recognition of diversealso expressed KIRsreactive with the same class I mole-
cules, this would complicate the interpretation of these class I molecules. It is tempting to speculate that the
94AP may represent functional homologs of the murinenegative results.
The disparate functional effects of anti-CD94 MAb on Ly49 receptors; however, this awaits the molecular char-
acterization of the 94AP.different NK cell clones might be explained either by
structural heterogeneity of the CD94 molecule itself or
association with another molecule responsible for HLA
Experimental Proceduresbinding and signal transduction. We previously demon-
strated that the CD94 cDNA lacks a cytoplasmic domain
NK Cell Clones
(Chang et al., 1995), and in further experiments we were NK cell clones (CD32, CD561) were isolated from the blood of healthy
unable to identify other CD94 isoforms containing a adults by single cell cloning using a flow cytometer (Becton Dickin-
longer cytoplasmic region (unpublished data). Another son Immunocytometry Systems, San Jose, California). Cells were
cultured as described previously (Litwin et al., 1993; Yssel et al.,unexpected finding was an apparent discrepancy in the
1984).predicted sizeof the protein encoded by the CD94 cDNA
(Chang et al., 1995) and the protein detected on the
surface of 125I-labeled NK cells by immunoprecipitation Antibodies
with anti-CD94 MAb (Aramburu et al., 1990). We now DX22 (an IgG1 MAb against human CD94) and DX24 (an IgG1 MAb
against human KIR also reactive with GL183 MAb) were generatedpresent evidence suggesting that CD94 receptors are
by immunizing BALB/c mice with an NK cell clone andfusing spleno-heterodimers composed of z30 kDa CD94 subunits
cytes with the Sp2/0 myeloma cell line using standard techniques.disulfide-bonded to novel CD94-associated proteins
Anti-KIR MAbs GL183 and EB6 (Moretta et al., 1990) were provided
(94AP)of z43 kDathat are tyrosine phosphorylated after by Drs. L. and A. Moretta. Anti-CD94 MAbs HP-3D9 and HP-3B1
NK cell activation (thus implying the existence of a cyto- (Aramburu et al., 1990; Lopez-Botet, 1995) and anti-KIR MAb HP-
plasmic region and possible involvement in signal trans- 3E4 (Melero et al., 1994) were provided by Dr. M. Lopez-Botet. Anti-
HLA class I MAbs DX15 and DX17 (both murine IgG1) were describedduction). The observation that the z43 kDa 94AP readily
previously (Gumperz et al., 1995; Phillips et al., 1995). Other MAbslabel with 125I, whereas the CD94 proteins are difficult
were the gift of Becton Dickinson Immunocytometry Systems.to visualize by 125I labeling suggests the extracellular
F(ab9)2 fragments of murine IgG1 MAb were prepared by digestionregion of the 94AP also differs from CD94. Furthermore,
with immobilized pepsin (Pierce Chemicals, Rockford, Illinois) (10
a polyclonal rabbit antiserum generated against the en- mg immunoglobulin in 0.2 M sodium citrate, 0.15 M sodium chloride
tire extracellular domain of a recombinant CD94 glyco- [pH 3.5] were added to 1 ml immobilized pepsin and incubated at
protein did not bind to the z43 kDa 94AP. However, this 378C for 2 hr). Intact antibodies were removed by using protein A
affinity chromatography and the purity of the F(ab9)2 fragments waspolyclonal anti-CD94 serum did detect a glycoprotein of
determined by SDS–PAGE.the size predicted from the CD94 cDNA in all NK cell
lines and clones examined, demonstrating that a CD94
antigen reactive with the polyclonal antiserum is present Immunofluorescence and Flow Cytometry
in these NK cells. It is possible that the z43 kDa 94AP These methods have been described previously (Lanier and Reck-
tenwald, 1991).are isoforms of the CD94 gene generated by alternative
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Cytotoxicity Assays G–Sepharose (Sigma) or Pansorbin (Calbiochem, San Diego, Califor-
nia), as described previously (Lanier et al., 1988), and were washedCell-mediated cytotoxicity was measured using a 4 hr 51Cr radioiso-
tope release assay (Lanier et al., 1995). Alternatively, cytotoxicity in stringent wash buffer (50 mM Tris, 150 mM NaCl [pH 8.5]) con-
taining 1% Triton X-100 (Sigma), 0.1% SDS (Bio-Rad, Richmond,was monitored using an Alamar blue viability assay. In this assay,
effector cells at various concentrations were combined with 4 3 California), 1% sodium deoxycholate (Sigma), and protease inhibi-
tors. In some experiments,anti-CD94 MAbswere covalently coupled104 target cells in flat-bottomed 96-well microtiter plates (Falcon,
Lincoln Park, New Jersey) and incubated at 378 for 18 hr. Alamar to protein G–Sepharose by using 10 mM dimethyl pimelimidate–
2HCl (DMP, Pierce), as described by Schneider et al. (1982). Immu-blue (Alamar Biosciences, Sacramento, California) was added to
each well (25 ml Alamar blue/well) and the plates were incubated at noprecipitates were incubated for 18 hr at 378C with an optimal
concentration of N glycosidase F(Boehringer Mannheim, Indianapo-378C for an additional 4–6 hr with occasional mixing. After incuba-
lis, Indiana), using the conditions recommended by the suppliertion, the absorbance was measured at 570 nm and 600 nm using
to remove N-linked oligosaccharides. Samples were analyzed bya 96-well microtiter plat reader (V Max kinetic microplate reader,
SDS–PAGE (Bio-Rad or Novex, San Diego, California) and radioac-Molecular Devices, Menlo Park, California). Percent viability was
tivity was detected using a PhosphorImager (Molecular Devices,determined according to the following equation: Percent viable tar-
Sunnyvale, California). For Western blot analysis, cell lysates (1 3get cells 5
108 cells/ml in 1% NP-40 lysis buffer) or immunoprecipitates were
absorbance (600 nm 2 570 nm) of effector 1 solubilized in sample buffer (62.5 mM Tris [pH 6.8], 2.3% SDS, 10%
target cells 2 absorbance of effector cells only glycerol, with orwithout 5% 2-mercaptoethanol),separated by SDS–
3 100
absorbance of target cells alone PAGE, and transferred to PVDF membranes (Immobilon-P, Millipore,
Bedford, Massachusetts) in transfer buffer (25 mM Tris, 192 mM
Controls consisted of target cells incubated in the absence of ef- glycine, 20% methanol). Membranes were incubated overnight at
fector cells and effector cells incubated without target cells. room temperature in blocking buffer (15 mM Tris, 150 mM NaCl
[pH 8.0]), containing 0.05% NaN3, 0.5 g/ml MgCl2, 0.5% Tween 20
(Sigma), and 10% nonfat dry milk (Carnation, Nestle Food Company,Polyclonal CD94 Antisera
Glendale, California) and then were incubated for 2 hr at room tem-A chimeric IgG Fc–CD94 fusion protein was produced by inserting
perature with blocking buffer containing primary antibodies (1 mg/a cDNAencoding the extracellular (EC) domain of CD94 (amino acids
ml). Blots were washed three times for 5 min in wash buffer (15 mM44–179) (Chang et al., 1995) into the pMECD8Ig vector (provided by
Tris, 150 mM NaCl [pH 8.0]), containing 0.5 g/ml MgCl2 and 0.5%Dr. K. Moore), a derivative of the SRa expression vector (Takebe et
Tween 20, and then incubated for 45 min at room temperature inal., 1988), containing a CD8 leader segment and a human IgG Fc
20 ml wash buffer containing 1/1000 horseradish peroxidase (HRP)-fragment. Because CD94 is a type II protein, the human IgG Fc–CD94
conjugated F(ab9)2 donkey anti-rabbit immunoglobulin (Amersham),EC fusion protein was constructed with the IgG Fc fragment at the
3% bovine serum albumin (Sigma), 50 ml pooled human serum (Pel-N terminus and the CD94 EC at the COOH terminus of the fusion
Freez, Brown Deer, Wisconsin) and 50 ml fetal bovine serum (Sigma).protein. This was achieved by using oligonucleotide primers to am-
Blots were washed twice in wash buffer and once in wash bufferplify the EC domain of CD94 that contained an XhoI restriction
containing 0.5 M NaCl and 0.1% SDS and then developed for 1 minenzyme site at the 59 end of the sense primer and a NotI restriction
at room temperature with SuperSignal CL-HRP substrate (Pierce).enzyme site after the CD94 termination codon in the antisense
Chemiluminescence was detected by autoradiograph (BioMax Film,primer. The pMECD8IgG vector was digested with XhoI and NotI
Kodak).and the CD94 EC cDNA was inserted by ligation immediately after
For detection of phosphorylated proteins, cells were incubatedthe IgG Fc fragment. The CD8IgG–CD94 EC cDNA was sequenced
at 378C for 10 min in phosphate-buffered saline (pH 7.4) containingto confirm the construction. Recombinant protein was generated
freshly prepared sodium pervanadate (100 mM sodium orthovana-by transient expression in COS7 cells and was affinity purified from
date and 10 mM H2O2, Sigma) (O’Shea et al., 1992) and then lysedsupernatants using protein A–Sepharose chromatography. Rabbits
in 1% NP-40 Tris-buffered saline (50 mM Tris, 150 mM NaCl [pH(Babco, Berkeley, California) were immunized with the IgG Fc–CD94
8.0]) with protease inhibitors (1 mM PMSF and 20 Kallikrein inhibitorEC fusion protein and specific antibodies were affinity purified by
U/ml aprotinin) and phosphatase inhibitors (1 mM EGTA, 10 mMbinding to IgG Fc–CD94 EC fusion protein covalently linked to CNBr-
sodium fluoride, 1 mM tetrasodium pyrophosphate, 0.1 mM b-glyc-activated Sepharose. Rabbit antibodies were absorbed with human
erophosphate, 1 mM sodium orthovanadate) (Lanier et al., 1988).immunoglobulin and serum proteins (50% saturated ammonium sul-
Lysates were precleared and CD94 proteins were immunoprecipi-fate–precipitated proteins from normal human serum) covalently
tated with immobilized anti-CD94 MAb (Lanier et al., 1988). Immuno-coupled to CNBr–Sepharose. Affinity-purified rabbit anti-CD94 anti-
precipitates were electrophoresed on 4%–20% acrylamide gels,bodies specifically reacted with human CD94, as determined by
blotted to PVDF membranes, and phosphorylated proteins detectedimmunofluorescence and Western blot analysis using CD94
by using HRP-conjugated anti-phosphotyrosine MAb PY20 (Zymed,transfectants.
South San Francisco, California) or HRP-conjugated anti-phospho-
tyrosine MAb 4G10 (UBI, Lake Placid, New York). Blots were incu-
Transfectants bated at room temperature for 2 hr in 1 mg/ml MAb in 15 mM Tris,
The MHC class I–deficient EBV-transformed B lymphoblastoid cell 150 mM NaCl, (pH 8.0), containing 0.5 g/ml MgCl2, 0.5% Tween 20,
line 721.221 (Shimizu and DeMars, 1989) was provided by Drs. R. and 5% bovine serum albumin.
DeMars. 721.221 cells were stably transfected with HLA-A, HLA-B,
and HLA-C cDNA, as described previously (Gumperz et al., 1995; Acknowledgments
Litwin et al., 1993). Transfectants were routinely monitored for ex-
pression of surface HLA class I by flow cytometry. The murine mas- We thank S. Lazetic for expert assistance with tissue culture and
tocytoma cell line P815 was stably transfected with CD94 cDNA hybridoma production and J. Cupp, D. Polakoff, and E. Callas for
(Chang et al., 1995) in the pBJ expression vector (Lin et al., 1990). expert assistance with flow cytometry. DNAX Research Institute is
supported by Schering Plough Corporation. This work was sup-
Biochemistry ported by National Institutes of Health training grant GM07276 to
Cells were labeled with 125I (Amersham, Arlington Heights, Illinois) J. E. G. and National Institutes of Health grant AI22039 to J. E. G.
using glucose oxidase and lactoperoxidase and lysed in 1% NP-40 and P. P.
(Sigma Chemicals, St. Louis, Missouri) lysis buffer (50 mM Tris, 150
mM NaCl [pH 8.0]) containing protease inhibitors (1 mM PMSF and Received May 15, 1996; revised July 3, 1996.
20 Kallikrein inhibitor U/ml aprotinin) and phosphatase inhibitors (1
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